FiercePharma

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Standing toe-to-toe with giants is nothing to sniff at, but bagging an outright advantage is something else: Just ask Eli Lilly's Taltz, which notched a head-to-head victory against AbbVie's behemoth ...
WFMZ-TV

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis

Psoriatic arthritis (PsA) is a chronic, progressive form of inflammatory arthritis that can cause swelling, stiffness and pain in and around the joints and impaired physical function. 2 It occurs when ...
FiercePharma

Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contest

Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Friday, the ...
Seeking Alpha

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...